Edesa Biotech, Inc. files 10-K annual report with SEC.
Edesa Biotech, Inc., a pharmaceutical company specializing in drug development, has recently filed its 10-K annual report with the Securities and Exchange Commission. The filing provides detailed information about the company’s financial performance and operations for the fiscal year ending on September 30, 2024. Included in the filing are various exhibits such as Form 10-K, Exhibit 3.7, and Exhibit 4.11 which offer additional insights into the company’s activities and financial status.
Attachments:
1. Form 10-K
2. Exhibit 3.7
3. Exhibit 4.11
Additional Info:
– Mailing Address: 100 SPY COURT, MARKHAM A6 L3R 5H6
– Business Address: 100 SPY COURT, MARKHAM A6 L3R 5H6, Phone: (905) 475-1234
– CIK: 0001540159
– IRS No.: 000000000
– State of Incorp.: A1
– Fiscal Year End: 09/30
– Type: 10-K
– Act: 34
– File No.: 001-37619
– Film No.: 241549047
– SIC: 2834 Pharmaceutical Preparations
– CF Office: 03 Life Sciences
[Link to Edesa Biotech, Inc. Website](#)
